A radiotherapy source for treating a tumor, which includes a flexible core impermeable to radon and a polymer coating on the flexible core. The polymer coating is impermeable to radium, and allows diffusion of radon therethrough. The radiotherapy source also includes alpha-emitting radium radionuclides in the polymer coating or between the flexible core and the polymer coating.

A radioactive thermogel suspension, including a thermogel and a plurality of insoluble radioactive isotope phosphate particles, such as yttrium phosphate, suspended in the thermogel. The thermogel is PLGA-g-PEG. The thermogel contains less than 65 ppm stannous octanoate. The plurality of radioactive yttrium phosphate particles are between 0.03 m and 10 m in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 3 mg/ml to 100 mg/ml.

Polymeric compounds containing polymer backbones functionalized with ion-specific recognition elements and methods for the use of these compounds are described herein. The polymeric compounds may contain multiple types of ion-specific recognition elements depending on a specific application. The polymeric compounds can be used to remove ionic species from a solution, for example, in separations applications in which a single or multiple types of ionic species are desired to be removed from the solution.

A radioactive thermogel suspension, including a thermogel and a plurality of insoluble radioactive isotope phosphate particles, such as yttrium phosphate, suspended in the thermogel. The thermogel is PLGA-g-PEG. The thermogel contains less than 65 ppm stannous octanoate. The plurality of radioactive yttrium phosphate particles are between 0.03.Math.m and 10.Math.m in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 3 mg/ml to 100 mg/ml.

The embodiments of the present invention disclose a conjugate compound of formula X-J-MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof, preferably the invention relates to radiopharmaceutical compositions of .sup.99mTc. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.

The present invention relates to a somatostatin analogue composition for radiopharmaceutical use, in particular for diagnostic or therapeutic use. More specifically the somatostatin analogue is a receptor-selective somatostatin peptide antagonist.

This invention relates to a ceramic module for assembly into a therapeutic device for treating a human or animal body with irradiation of far infrared radiation and low dose ionizing radiation based on radiation hormesis effect. More specifically, the invention relates to a ceramic module that simultaneously emits far infrared radiation within 3-16 m wavelength spectrum and ionizing radiation at a specific dose rate in the range of 0.1-11 Sv/h (micro-Sieverts per hour). Said ceramic module may be used alone or serve as components of a therapeutic device for increasing physiologic performance, immune competence, health, and mean lifespan of human or animal.

This invention relates to a ceramic module for assembly into a therapeutic device for treating a human or animal body with irradiation of far infrared radiation and low dose ionizing radiation based on radiation hormesis effect. More specifically, the invention relates to a ceramic module that simultaneously emits far infrared radiation within 3-16 m wavelength spectrum and ionizing radiation at a specific dose rate in the range of 0.1-11 Sv/h (micro-Sieverts per hour). Said ceramic module may be used alone or serve as components of a therapeutic device for increasing physiologic performance, immune competence, health, and mean lifespan of human or animal.

A method of performing a radioembolization treatment includes injecting 402 a plurality of radioembolization particles into a bloodstream of a patient to treat a target tissue. Each radioembolization particle of the plurality of radioembolization particles includes a radioactive core and a radiopaque layer. The method also includes obtaining 404 an image of the target tissue and the radioembolization particles to determine 406 a dose of radioactivity delivered to the target tissue by the plurality of radioembolization particles. wherein the image is one of a computerized tomography (CT) image and an x-ray image.

A radioactive yttrium phosphate suspension, including a phosphate buffered saline solution and a plurality of radioactive yttrium phosphate particles suspended in the phosphate buffered saline solution. The plurality of radioactive yttrium phosphate particles are between 0.1 um to 2 um in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 40 mg/ml to 125 mg/ml.